

# Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial

Josep-Maria Ribera,<sup>1</sup> Mireia Morgades,<sup>1</sup> Olga García-Calduch,<sup>1</sup> Maialen Sirvent,<sup>2</sup> Buenaventura Buendía,<sup>3</sup> Marta Cervera,<sup>4</sup> Hugo Luzardo,<sup>5</sup> Jesús-María Hernández-Rivas,<sup>6</sup> Marta Sitges,<sup>7</sup> Irene García-Cadenas,<sup>8</sup> Pau Abrisqueta,<sup>9</sup> Pau Montesinos,<sup>10</sup> Mariana Bastos-Oreiro,<sup>11</sup> María-Paz Queipo de Llano,<sup>12</sup> Pilar Bravo,<sup>13</sup> Anna Torrent,<sup>1</sup> Pilar Herrera,<sup>14</sup> Antoni Garcia-Guiñon,<sup>15</sup> Ferran Vall-llovera,<sup>16</sup> Josefina Serrano,<sup>17</sup> María-José Terol,<sup>18</sup> Juan-Miguel Bergua,<sup>19</sup> Ana García-Noblejas,<sup>20</sup> Cristina Barrenetxea,<sup>21</sup> Laura Llorente,<sup>22</sup> Daniel García-Belmonte,<sup>23</sup> Eva Gimeno,<sup>24</sup> Antonia Cladera,<sup>25</sup> Santiago Mercadal<sup>26</sup> and Juan-Manuel Sancho<sup>1</sup> on behalf of the PETHEMA and GELTAMO groups

<sup>1</sup>Department of Hematology, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Research Institute-Badalona, Universitat Autònoma de Barcelona, Barcelona;

<sup>2</sup>Department of Hematology, Hospital Universitario de Donostia, Donostia; <sup>3</sup>Department of Hematology, Hospital Universitario 12 de Octubre, Madrid; <sup>4</sup>Department of Hematology, Institut Català d'Oncologia-Hospital Joan XXIII, Tarragona; <sup>5</sup>Department of Hematology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria; <sup>6</sup>Department of Hematology, IBSAL, IBMCC, Centro de Investigación del Cáncer, CIBERONC, Universidad de Salamanca-CSIC, Hospital Universitario de Salamanca, Salamanca; <sup>7</sup>Department of Hematology, Institut Català d'Oncologia-Hospital Josep Trueta, Girona; <sup>8</sup>Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona; <sup>9</sup>Department of Hematology, Hospital Universitari Vall d'Hebron, Barcelona; <sup>10</sup>Department of Hematology, Hospital Universitari i Politècnic La Fe, Valencia; <sup>11</sup>Department of Hematology, Hospital General Universitario Gregorio Marañón, IISGM, Madrid; <sup>12</sup>Department of Hematology, Hospital Universitario Virgen de la Victoria, Málaga; <sup>13</sup>Department of Hematology, Hospital Universitario de Fuenlabrada, Madrid; <sup>14</sup>Department of Hematology, Hospital Universitario Ramón y Cajal, Madrid; <sup>15</sup>Department of Hematology, Hospital Universitari Arnau de Vilanova de Lleida, Lleida; <sup>16</sup>Department of Hematology, Hospital Universitari Mútua de Terrassa, Terrassa; <sup>17</sup>Department of Hematology, Hospital Universitario Reina Sofía, IMIBIC, Córdoba; <sup>18</sup>Department of Hematology, Hospital Clínico Universitario de Valencia, Valencia; <sup>19</sup>Department of Hematology, Hospital San Pedro de Alcántara, Cáceres; <sup>20</sup>Department of Hematology, Hospital Universitario de La Princesa, Madrid; <sup>21</sup>Department of Hematology, Hospital Universitario Basurto, Bilbao; <sup>22</sup>Department of Hematology, Hospital Universitario HM Sanchinarro, Madrid; <sup>23</sup>Department of Hematology, Hospital Universitario La Zarzuela, Madrid; <sup>24</sup>Department of Hematology, Hospital del Mar, Barcelona; <sup>25</sup>Department of Hematology, Hospital Universitari Son Llàtzer, Palma de Mallorca and <sup>26</sup>Department of Hematology, Institut Català d'Oncologia-Hospital Duran i Reynals, L'Hospitalet de Llobregat, Spain

**Correspondence:** J-M. Ribera  
[jribera@iconcologia.net](mailto:jribera@iconcologia.net)

**Received:** April 19, 2023.

**Accepted:** July 31, 2023.

**Early view:** August 10, 2023.

<https://doi.org/10.3324/haematol.2023.283342>

©2024 Ferrata Storti Foundation

Published under a CC BY-NC license



**Supplemental Table 1.** Comparison of the main clinical and biologic characteristics of patients aged 18-55 yrs. included in the BURKIMAB14 vs. BURKIMAB08 trials.

		<b>BURKIMAB08 (n=87)</b>	<b>BURKIMAB14 (n=68)</b>	<b>P</b>
<b>Gender, male n(%)</b>		63 (72)	55 (81)	0.220
<b>Age, yrs., median (min;max)</b>		42 (18 ; 55)	39 (18 ; 55)	0.448
<b>Diagnosis, n (%)</b>	Burkitt's leukemia	17 (19)	19 (28)	0.219
	Burkitt lymphoma	70 (81)	49 (72)	
<b>Ann Arbor stage, n (%)</b>	I – II	17 (19)	21 (31)	0.103
	III - IV	70 (81)	47 (69)	
<b>HIV infected, n (%)</b>		35 (40)	17 (25)	0.046
<b>ECOG &lt;2, n (%)</b>		45/86 (52)	48/66 (73)	0.011
<b>≥2 extranodal involvements, n (%)</b>		39 (45)	34 (50)	0.522
<b>CNS involvement, n (%)</b>		10 (11)	10 (15)	0.554
<b>Bulky mass (&gt;10 cm), n (%)</b>		28 (32)	24/65 (37)	0.542
<b>High LDH, n (%)</b>		79/85 (93)	46/66 (70)	<0.001
<b>IPI, n (%)</b>	Low / Low-Intermediate	33/86 (38)	35/67 (52)	0.087
	Intermediate / Intermediate-High	53/86 (62)	32/67 (48)	
<b>BL-IPI, n (%)</b>	Low	6/68 (9)	16/66 (24)	0.020
	Intermediate	18/68 (26)	21/66 (32)	
	High	44/68 (65)	29/66 (44)	

HIV: human immunodeficiency virus; ECOG: Eastern Cooperative Oncology Group; CNS: central nervous system; LDH: lactate dehydrogenase; IPI: International Prognostic Index; BL-IPI: Burkitt Lymphoma International Prognostic Index

**Supplemental Table 2.** Main grade >2 toxicity in the BURKIMAB08 vs. BURKIMAB14 trials in patients aged 18-55 yrs.

	<b>BURKIMAB08 (n=87)</b>	<b>BURKIMAB14 (n=68)</b>	<b>P</b>
<b>Neutropenia (Induction)</b> Median days (min; max)	79/83 (95%) 8 (1; 24)	64/66 (97%) 7 (1; 21)	0.694 0.074
<b>Thrombocytopenia (Induction)</b> Median days (min; max)	63/83 (76%) 6 (1; 25)	48/66 (73%) 3 (1; 31)	0.659 0.013
<b>Hepatic</b>	11/85 (13%)	5/66 (8%)	0.288
<b>Renal</b>	6/85 (7%)	3/66 (5%)	0.732
<b>Mucositis</b>	41/86 (48%)	29/66 (44%)	0.647
<b>Neurologic</b>	5/85 (6%)	2/66 (3%)	0.469
<b>Infections</b>	74 (85%)	45/65 (69%)	0.019
<b>Death by infection</b>	12 (14%)	2 (3%)	0.019